MOD GRF 1-29 Deus Medical is presented as a synthetic analogue of growth hormone-releasing hormone (GHRH), commonly identified in research literature as Modified GRF 1-29. It is also frequently associated with the term CJC-1295 without DAC. However, the naming can create confusion because CJC-1295 with DAC is a distinct construct. Therefore, customers researching this product should use the exact product name and available documentation when comparing listings.

MOD GRF 1-29 Deus Medical Product Information

MOD GRF 1-29 is a 29-amino-acid GHRH analogue designed with substitutions intended to alter peptide stability. Deus Medical currently describes its MOD GRF 1-29 product as a tetrasubstituted 29-amino-acid peptide hormone and lists CAS number 863288-34-0, molecular weight 3367.95 g/mol, and molecular formula C152H252N44O42. The manufacturer’s current page lists a 2 mg composition for its product, so the strength shown on your specific packaging should remain the definitive product specification.

Researchers have investigated GHRH analogues because GHRH participates in the regulation of growth hormone secretion. However, research involving CJC-1295 cannot automatically be applied to every MOD GRF 1-29 formulation. In particular, published human studies examined CJC-1295, including the longer-acting DAC form, rather than establishing clinical evidence for every commercially marketed no-DAC product.

Key Features and Specifications

The principal identifying feature is the MOD GRF 1-29 designation. Related terminology includes Modified GRF 1-29, Mod GRF, CJC-1295 without DAC, and CJC-1295 no DAC. These terms can help customers locate scientific references. Nevertheless, they should not replace product-specific verification.

For customers researching the Deus Medical listing, the most useful specifications include the stated peptide name, package strength, manufacturer information, lot number, and available analytical documentation. Moreover, the molecular formula and molecular weight published by Deus Medical provide additional identity references. However, those specifications do not independently establish the purity, sterility, potency, or authenticity of an individual commercial batch.

Research Context

Scientific literature has examined GHRH analogues in laboratory and clinical research. For example, a 2006 PubMed-indexed study investigated CJC-1295 in healthy adults and reported effects on growth hormone and IGF-I concentrations. Importantly, that study involved CJC-1295, not necessarily the exact commercial MOD GRF 1-29 material represented by this listing. Therefore, those findings should not be presented as proof of benefits from a specific Deus Medical product.

Likewise, analytical research has examined the detection of synthetic GHRH analogues, including CJC-1295 and related compounds. This research demonstrates why accurate compound identification matters when comparing peptide products and scientific terminology.

Sports regulations also deserve attention. The World Anti-Doping Agency includes GHRH and its analogues within its prohibited peptide-hormone and releasing-factor category. Consequently, athletes subject to anti-doping rules should check the current rules of their governing organization before considering products associated with GHRH analogues.

Product Evaluation and Ordering

When evaluating MOD GRF 1-29 Deus Medical, focus on verifiable product information rather than unsupported claims about muscle growth, recovery, fat loss, performance, or other outcomes. Furthermore, compare the stated strength with the original packaging and available batch documentation. Likewise, customers should check applicable regulations because peptide products can have different legal classifications across jurisdictions.

Iron Elite Nutrition can provide the relevant product listing and ordering information. Before purchasing, review the product name, stated specification, manufacturer details, and documentation available for the specific batch.

Overall, MOD GRF 1-29 Deus Medical is best described as a Modified GRF 1-29 GHRH analogue with a documented research identity. The product should remain distinct from CJC-1295 with DAC, and published findings for one form should not automatically transfer to another. Therefore, accurate product descriptions should emphasize identity, specifications, research context, and documentation rather than guarantees or unsupported health claims.

Additionally, using precise terminology improves search visibility and reduces confusion. For example, customers may search for MOD GRF 1-29, Modified GRF 1-29, CJC-1295 no DAC, or GHRH analogue. Clear wording helps readers find relevant scientific information while maintaining an accurate product page. If you are researching this listing, compare the package label with the available documentation and consult reputable scientific and regulatory sources for additional context before making decisions about the product.